This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Seqirus Inc.
Seqirus Inc., a leading global player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia-Pacific. Founded in 2015, Seqirus emerged from the merger of Novartis Vaccines and the bioCSL division of CSL Limited, quickly establishing itself as a key innovator in the field of vaccines and immunotherapy. Specialising in the development and production of influenza vaccines, Seqirus is renowned for its cutting-edge technologies and commitment to public health. The company’s unique offerings, such as its adjuvanted flu vaccines, enhance immune responses, making them particularly effective for vulnerable populations. With a strong market position, Seqirus has achieved notable milestones, including significant contributions to pandemic preparedness and a robust portfolio of seasonal flu vaccines, solidifying its reputation as a trusted leader in vaccine innovation.
DitchCarbon Score
How does Seqirus Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Seqirus Inc.'s score of 46 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Seqirus Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of CSL Limited, Seqirus inherits emissions data and climate commitments from its parent company. CSL Limited has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Seqirus Inc. are not detailed in the available information. As part of its commitment to sustainability, Seqirus is aligned with the broader climate strategies of CSL Limited, which may include industry-standard practices aimed at reducing carbon emissions across Scope 1, 2, and 3 categories. The absence of specific emissions data suggests that Seqirus is in the process of developing its own climate action framework, reflecting the growing emphasis on corporate responsibility in the biopharmaceutical sector. Overall, while Seqirus Inc. does not currently report specific emissions figures, its affiliation with CSL Limited positions it within a framework of established climate commitments and initiatives aimed at reducing environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Seqirus Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
